二甲双胍对肥胖及非肥胖PCOS妇女内分泌的影响

Efficacy of Metformin in Obese and Non-obese Womenwith Polycystic Ovary Syndrome

目的:分析肥胖及非肥胖多囊卵巢综合征(PCOS)患者的内分泌特征,探讨应用二甲双胍治疗对两类患者临床症状及内分泌指标的影响。方法:按体重指数(BMI)将43例PCOS患者分为肥胖组23例,非PCOS肥胖组20例,比较BMI、FPG、FINS及FSH、LH及T;两组均服用二甲双胍3个月,观察治疗前后临床症状及内分泌指标的改善情况。结果:肥胖组BMI、FINS及HOMA-IR明显高于非肥胖组(P<0.01),而非肥胖组LH高于肥胖组(P<0.05)。二甲双胍治疗后肥胖组BMI降低(P<0.01),FSH升高(P<0.05),LH、FPG、FINS和HOMA-IR均明显降低(P<0.01)。而非肥胖组BMI及FPG无改变。结论:肥胖与非肥胖PCOS患者内分泌特征不同,二甲双胍可明显改善肥胖及非肥胖PCOS患者的临床症状和内分泌指标,尤其适用于肥胖PCOS患者。

Objective： To analyze the endocritic profiles of obese and non - obese women with polycystic ovary syndrome （ PCOS）, and study the effects of mefformin on those patients. Methods： Forty- three women with PCOS were divided into two groups depend on BMI which were obese group and non - obese group, and were treated with mefformin for three months. Body mass index（BMI）, the situation of menstruation cycle, the degree of acne, Ferriman - Gallwey score, as well as gonadotropine（ FSH, LH）, testosterone （T）, fasting insuline, fasting plasma glucose and HOMA -IR were measured in all patients before and after treatment. Results： The levels of BMI, FINS and HOMA - IR were significantly higher in obese group than those in non- obese group（ P 〈 0.01 ）, while LH level was higher in non -obese group than that in obese group （P 〈 0. 05 ）. After three months of treatment, in obese group, BMI level was decreased but FSH level was increased （ P 〈 0.05 ）, and the levels of LH, FPG, FINS and HOMA - IR were decreased in different degrees（P 〈0.01 ）, but BMI and FPG levels were showed no significant changes in non -obese group. Conclusion： Endocritic profiles in obese PCOS patients are different from those in non - obese PCOS patients, and mefformin are effective on patients with obese or non - obese PCOS, especially applicable to obese PCOS patients.